Doravirine/lamivudine/tenofovir

Doravirine/lamivudine/tenofovir is a medication used for the treatment of HIV/AIDS. It is a fixed-dose combination of doravirine, lamivudine, and tenofovir disoproxil.

Etymology

The name "Doravirine" is derived from the chemical structure of the drug, which is a non-nucleoside reverse transcriptase inhibitor (NNRTI). "Lamivudine" is derived from its chemical name, (2R-cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one. "Tenofovir" is derived from its chemical name, (R)-9-(2-Phosphonylmethoxypropyl)adenine.

Medical uses

Doravirine/lamivudine/tenofovir is used in the treatment of HIV-1 infection in adults. It is recommended as an initial regimen for individuals who have no history of antiretroviral treatment and no known substitutions associated with resistance to the individual components of the drug.

Side effects

Common side effects include nausea, diarrhea, headache, fatigue, and abdominal pain. Serious side effects may include liver problems, kidney problems, and new or worsening mental health problems.

Pharmacology

Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), while lamivudine and tenofovir are nucleoside reverse transcriptase inhibitors (NRTIs). They work by blocking the action of reverse transcriptase, an enzyme that the HIV virus needs to reproduce itself.

History

Doravirine/lamivudine/tenofovir was approved for medical use in the United States in August 2018. It is marketed under the brand name Delstrigo by Merck & Co.

See also

• Antiretroviral therapy
• HIV/AIDS
• Reverse transcriptase inhibitor

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia